Pliant shares spike on exploratory study results of lead drug in chronic liver disease
Pliant Therapeutics shared early-stage biomarker and imaging results, suggesting that patients with a chronic liver disease who received its drug had improved liver function compared to those who received a placebo.
In the Phase IIa study results announced Tuesday, Pliant split 85 patients with primary sclerosing cholangitis (PSC) into four groups: 40 mg, 80 mg, and 160 mg of bexotegrast, as well as placebo. In an exploratory analysis, Pliant said that patients who received the three doses of bexotegrast saw reduced levels at 12 weeks of PRO-C3 and alkaline phosphatase — biomarkers of liver scarring.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.